Applied Vascular Engineering (US) starts Micro Stent trial
This article was originally published in Clinica
Applied Vascular Engineering (US) has started US trials of its Micro Stent following receipt of an Investigational Device Exemption from the FDA. SMART (Study of Micro Stent's Ability to Limit Restenosis Trial) will compare Micro Stent to J&J's Palmaz-Schatz stent in de novo lesions at 20 centres. Enrolment of patients is expected to take six months. Like the Benestent II heparin-coated stent trial (see Clinica No 669/70, p 24), SMART includes ticlopidine antiplatelet therapy in its protocol.